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Objective: We tested the hypothesis that rapamycin coated onto, and eluted from, expanded polytetrafluoroethylene
(ePTFE) grafts would diminish neointimal hyperplasia in a porcine model.
Methods: Rapamycin (also called sirolimus) was coated onto the luminal surface of 6-mm-internal-diameter thin-walled
ePTFE grafts by using an adhesive polymer that allows timed release of the drug. An adhesive polymer that allows timed
release of rapamycin from ePTFE was developed with commercially available chemicals and applied on 6-mm ePTFE
grafts. Graft integrity was characterized by scanning electron microscopy, and rapamycin levels were quantified by using
high-performance liquid chromatography. Twenty-two mongrel pigs were randomized into three groups: untreated
ePTFE (n  6), adhesive-only coated ePTFE (n  6), or adhesive- and rapamycin-coated ePTFE (n  10). End-to-side
unilateral aortoiliac bypasses were performed by using 6-mm-internal-diameter ePTFE grafts and standardized anasto-
motic lengths. Unilateral end-to-side aortoiliac ePTFE grafts (6-mm internal diameter) were inserted by using polypro-
pylene sutures, 6-0 proximally and 7-0 distally; all anastomoses were 12 mm long. All animals received aspirin (325 mg
orally) daily. All animals were given oral aspirin (325 mg) daily beginning on the day before surgery. At 28 days, the
animals were killed, and the grafts were explanted in continuity with the adjacent aortic cuff and the outflow iliac artery.
Variables compared between groups included graft patency, distal anastomotic length and cross-sectional narrowing, and
intimal thickness at the arterial-graft junction indexed to the adjacent graft thickness. Microscopic analysis was performed
with hematoxylin and eosin and Masson trichrome stains on paraffin sections. A pathologist blinded to experimental
groups graded sections for collagen deposition, neointima formation, inflammatory cellular infiltrates, medial necrosis,
and aneurysmal degeneration.
Results: All animals survived until they were killed without clinical evidence of limb ischemia or graft infection.
Preplanned t tests in the context of one-way analysis of variance showed no difference in outcome measures between the
untreated ePTFE and adhesive-only coated ePTFE groups; therefore, they were combined in further comparisons with
the adhesive- and rapamycin-coated ePTFE group. The Rapamycine eluting expanded polytetrafluoroethylene group had
longer anastomoses (85.6% vs 60.6% of the initial anastomotic length maintained; P < .0001) and less cross-sectional
narrowing in the outflow graft (16.2% vs 28.5%; P  .0007) when compared with the other two groups by using
two-tailed Student t tests. There was no evidence of medial necrosis or aneurysmal degeneration. All patent grafts had
complete endothelialization on hematoxylin and eosin sections. Rapamycin was detectable and quantifiable in the arterial
wall at 28 days after implantation.
Conclusions: Rapamycin can be coated onto and eluted from ePTFE by using a nonionic polymer and a simple coating
technique. At 4 weeks after implantation, the rapamycin-eluting ePTFE grafts demonstrate gross, pathologic, and
morphometric features of diminished neointimal hyperplasia when compared with non–drug-eluting ePTFE. Four weeks
after implantation in a porcine model, rapamycin-eluting ePTFE grafts demonstrated gross, pathologic, and morpho-
metric features of diminished neointimal hyperplasia when compared with untreated and adhesive-only coated ePTFE
grafts. ( J Vasc Surg 2005;42:980-8.)
Clinical Relevance: Rapamycin-eluting ePTFE grafts decrease neointimal hyperplasia in a porcine model. Further studies
are needed to evaluate whether patency will be improved. Rapamycin-eluting ePTFE grafts may allow the use of
prosthetic grafts in situations in which autologous vein is unavailable and in which neointimal hyperplasia is pronounced,
such as in small-diameter (<6-mm) vessels typical of infrapopliteal interventions.From the Department of Surgery, University of Tennessee Health Sciences
Center.
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980Although autologous saphenous vein is the best con-
duit for peripheral arterial reconstruction, 30% of patients
do not have this option as a result of prior vein harvest,
trauma, or phlebitis.1 Synthetic grafts made of expanded
polytetrafluoroethylene (ePTFE) have been used as substi-
tutes but have low patencies in vessels with diameters less
than 6 mm because of early thrombosis or late graft failure
from neointimal hyperplasia.2 Infrapopliteal ePTFE grafts
have primary patency rates at 4 years as low as 12%.3
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(PTA) is a multifactorial response to local injury involving
elastic recoil, negative arterial remodeling, and neointimal
formation. Stent technologies help to overcome elastic
recoil and negative arterial remodeling associated with ves-
sel injury, but there continues to be a 20% to 50% rate of
restenosis because the continuing pressure exerted by
stents against the vessel wall stimulates an increased arterial
proliferative response.4 One approach to combat neointi-
mal hyperplasia uses the elution of drugs with antiprolifera-
tive properties at the site of vessel injury. Coronary stents
that elute rapamycin at the site of angioplasty have reduced
neointimal hyperplasia, as evidenced by a decreased inci-
dence of major adverse coronary events and by a reduction
in binary restenosis, defined as a greater than 50% diameter
stenosis of the target lesion.5-8 Stents have not performed
as favorably in the infrainguinal circulation.
Expanded PTFE is able to withstand the biomechanical
forces that are exerted on it in the peripheral circulation
without the structural damage (such as fractures) that has
been reported when stents are placed in the superficial
femoral artery.9 Nontextile ePTFE grafts are manufactured
by an expansion process that transforms an initial full-
density polytetrafluoroethylene (PTFE)matrix into a struc-
ture composed of PTFE nodes interconnected by fine
fibrils, which allow tissue ingrowth. The resulting expanded
tube contains approximately 15% pure PTFE and 85% air
by volume. The PTFE polymer is, for the most part, chem-
ically inert; moreover, the grafts exhibit little tendency to
dilate, have a strong electronegative luminal charge, and are
hydrophobic until wetted by body fluids.10 Coating ePTFE
must not change the handling characteristics of the pros-
thetic because poor healing, inflammation, and thrombosis
may result. We hypothesized that rapamycin eluted from
prosthetic grafts would decrease neointimal hyperplasia by
reducing tissue ingrowth and preserving anastomotic diam-
eter. Thus, we attempted to coat ePTFE with rapamycin to
see whether, by local elution, anastomotic neointimal hy-
perplasia could be decreased without increasing thrombosis
or delaying healing.
MATERIALS AND METHODS
Rapamycin (Supelco, Bellefonte, Pa) was coated onto
ePTFE by using methodology developed at the University
of Tennessee Health Sciences Center. The details of the
coating technique have been submitted for an institutional
patent. Precut segments of 6-mm thin-walled ePTFE grafts
provided by Impra/Bard Peripheral Vascular (Tempe,
Ariz) were coated with rapamycin for 1 cm at both ends on
the luminal surface. The rapamycin was suspended in a
mixture of methacrylates. The coating was 5 to 10 m
thick. The ultrastructure of the ePTFE was assessed by
scanning electron microscopy. The rapamycin was eluted
over a 30-day period. The concentration of rapamycin was
250 g/cm2 or 1 mg of rapamycin per bypass graft. Grafts
were sterilized with ethylene oxide before implantation.
In preliminary experiments, rapamycin-eluting grafts weresent for drug quantification both before and after ethylene
oxide sterilization.
Preimplantation and postexplantation grafts, blood,
and tissues were sent to the high-performance liquid chro-
matography (HPLC) Drug Monitoring Laboratory at the
University of Texas Medical School at Houston for rapa-
mycin level quantification. Analyses were performed with
HPLC/UV assays developed by Dr Kimberly L. Napoli,
the director of the laboratory.11 Whole blood was collected
on the first three postoperative days and at death to quan-
titate systemic exposure to rapamycin. To confirm elution
of rapamycin from the ePTFE and deposition of drug in the
native arterial wall, explanted grafts and adjacent iliac artery
were snap-frozen in liquid nitrogen. The tissues were pack-
aged on dry ice and sent for rapamycin quantification. The
kinetics of elution were extrapolated by killing nine animals
(n 3 per time point) on postoperative days 7, 14, and 28.
These animals were separate from the 22 animals used to
evaluate changes in neointimal hyperplasia.
All animal care and procedures were performed in
accordance with the guidelines of the University of Ten-
nessee’s Institutional Animal Care and Utilization Com-
mittee. The animal procedures and care complied with the
Guidelines for the Care and Use of Laboratory Animals
(National Institutes of Health Publication No. 80-23, re-
vised 1985). Twenty-two mongrel pigs (Nichols Hog
Farm, Olive Branch, Mississippi) were housed in the animal
care facility of the Department of Comparative Medicine at
the University of Tennessee. All animals were male and
weighed from 17 to 27 kg. Food and water were provided
ad libitum. Animals were fed 325 mg of aspirin daily from
the day before surgery until death. Before surgery, animals
were given 1 g of cefazolin intravenously and cephalexin
500 mg by mouth twice a day for the first five postoperative
days. Aortoiliac bypass grafts using 6-mm thin-walled
ePTFE were performed under general anesthesia through a
midline laparotomy. Anesthesia was induced with intra-
muscular Telazol reconstituted with xylazine andwasmain-
tained with 1% isoflurane (Rhone-Poulenc, Bristol, UK).
Before arterial clamping, a bolus of heparin (110 U/kg)
was administered intravenously, after which supplemental
heparin (55 U/kg) was given at 30-minute intervals until
the completion of surgery. The anastomoses were 12 mm
long and had an end-to-side configuration. The aortic
anastomoses were performed with 6-0 polypropylene, and
the iliac anastomoses were performed with 7-0 polypro-
pylene. The intervening native iliac artery was doubly li-
gated. The animals were divided into three groups: animals
that received bypasses with uncoated ePTFE (U-eP; n 6),
animals that received bypasses with adhesive-coated ePTFE
(A-eP; n  6), and animals that received bypasses with
rapamycin-eluting ePTFE (R-eP; n 10). All animals were
killed on postoperative day 28.
At death, the bypass grafts and adjacent iliac and aortic
segments were removed in continuity. The iliac artery was
opened longitudinally along the vessel wall opposite the
anastomosis, pinned to in vivo dimensions, and placed in
10% formalin. Immediately after explantation, the length of
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percentage of maintained anastomotic length was calcu-
lated (explant anastomotic length/12). Two surgeons not
blinded to experimental groups measured the explanted
anastomotic length and averaged their values for each ani-
mal. Specimens were not perfusion-fixed because samples
were thin, usually 3 to 5 mm thick, which allowed for rapid
formalin fixation. All specimens were collected and pro-
cessed in a similar fashion. Absolute measurements were
not evaluated. Variables examined relative proportions or
ratios between groups. After a minimum of 24 hours of
soaking in 10% formalin (Baxter Diagnostics, McGaw Park,
Ill), the iliac segments were cross-sectioned at the heel and
placed in cassettes. Paraffin processing was performed by
pathology technicians from the Department of Pathology
at the University of Tennessee Health Sciences Center.
After paraffin embedding, two to three (5 m each) sec-
tions were stained with hematoxylin and eosin (H&E) or
Masson trichrome and used for morphometric analysis or
pathologic grading.
Morphometric comparisons were made by using Image
J (version 1.30). This software was downloaded from the
National Institute of Health’s Web site (http://rsb.info.
nih.gov/ij/). Measurements were made from cross sec-
tions taken at the heel of the iliac anastomoses. Tissue
blocks were generated from here because the hyperplastic
response was most pronounced to the naked eye, and the
sectioning resulted in a circular cross section of the ePTFE
that allowed for consistency during pathologic grading and
morphometric analysis. H&E-stained or Masson trichrome–
stained paraffin sections were mounted on slides and
viewed with the 2 objective on a Zeiss microscope (Carl
Zeiss Inc, Oberkochen, Germany). Fields were photo-
graphed with a Camedia D-540 ZOOM digital camera
(Olympus, Melville, New York). The digital images were
analyzed with Image J to determine differences in morpho-
metric criteria of neointimal hyperplasia. Themorphometry
analysis was performed by a researcher blinded to experi-
mental groups.
The percentage of cross-sectional narrowing attributed
to neointimal hyperplasia and the degree of neointimal
thickness at the arterial-graft junction indexed to ePTFE
graft thickness were compared between groups of animals.
The percentage of cross-sectional narrowing was calculated
by dividing the neointimal area by the area bound by the
inner table of the cross-sectioned ePTFE. The neointimal
area was calculated by subtracting the luminal area from the
area bound by the inner table of the cross-sectioned
ePTFE:
% Cross-sectional narrowing internal ePTFE area
 luminal area ⁄ internal ePTFE area
The intimal thickness index was calculated by dividing
the thickness of neointima at the heel of the iliac anasto-
mosis by the cross-sectional thickness of the ePTFE graft.
The measurement was performed where the internal elastic
lamina of the native artery was disrupted by the polypro-
pylene suture used to perform the anastomosis. Measure-ments for percentage of cross-sectional narrowing and in-
timal thickness index are presented as mean  SEM.
Semiquantitative histologic grading of H&E and Mas-
son trichrome sections was performed by a pathologist
blinded to experimental groups (C.R.H.). Features exam-
ined included endothelialization, spindle cell ingrowth, and
neointimal formation. Grading was performed as follows:
0, none of the luminal circumference of the graft involved;
1, less than 25% of the luminal circumference of the graft
involved; 2, 25% to 75% of the luminal circumference of the
graft involved; and 3, greater than 75% of the luminal
circumference of the graft involved. Immunostains for
-actin and factor VIII–related antigen to identify smooth
muscle cells and endothelial cells were not performed. The
pathologist examined sections with the 40 power objec-
tive and identified endothelial cells on the basis of surface
location and flattened cellular morphology. Spindle cells
were characterized with Masson trichrome as elongated
cells with purple cytoplasm that populated regions of extra-
cellular matrix (ECM). Ingrowth of spindle cells was used
to correlate with vascular smooth muscle cell (VSMC)
migration. The presence of spindle cells and ECM, which
stains blue or pink with Masson trichrome, depending on
collagen content, was used to designate areas of neointimal
formation on the ePTFE inner surface.
Statistical analysis was performed with SAS 9.0 (SAS
Institute Inc, Cary, NC) statistical software. First, pre-
planned contrasts in the context of one-way analysis of
variance (that are equivalent to two-tailed t tests with the
square root of the mean square error used as the pooled
standard deviation) were used to demonstrate that there
was no statistical difference between the U-eP and the A-eP
groups. Next, the data were combined into one control
group (n 12). Finally, data from the R-eP group (n 10)
were then compared with data from the combination of the
U-eP and A-eP groups (n  12; Table I) by using two-
tailed unpaired t tests with equal variances. Differences
were considered significant at P  .05. Variables are pre-
sented as mean  SEM.
Reproducibility of measurements was assessed for the
Table I. Comparison of gross pathologic and
morphometric parameters (postoperative day 28) of
neointimal hyperplasia between animals treated with
uncoated (U-eP) and adhesive-coated expanded
polytetrafluoroethylene (A-eP) and with rapamycin-
eluting expanded polytetrafluoroethylene (R-eP)
Variable
U-eP and
A-eP (n  12)
R-eP
(n  10) P value
% Initial anastomotic
length 60.6%  2.3% 85.6%  2.5% .0001
% Cross-sectional
narrowing 28.5%  2.7% 16.2%  3.0% .007
Intimal thickness
index 1.75  0.13 1.22  0.14 .01percentage of cross-sectional narrowing, ePTFE graft thick-
(orig
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standard deviation for percentage of cross-sectional narrow-
ing was 3.5%; the intraclass correlation coefficient was 0.84,
indicating excellent reproducibility. For ePTFE graft thick-
ness and area, the pooled within-animal standard deviations
were 0.08 mm and 1.40 mm2, respectively. For ePTFE
graft thickness, the reproducibility was poor; however, the
reproducibility of the ePTFE internal graft area was mod-
erate, with an intraclass correlation coefficient of 0.71.
RESULTS
Examining sections of coated grafts with scanning elec-
tronmicroscopy, we found that the coating was adherent to
the nodal islands of the ePTFE and did not obliterate the
internodal fibrils (Fig 1). The scanning electron microscopy
studies showed that rapamycin was encapsulated in the
matrix of polymeric adhesives. Rapamycin appeared as
speckling on nodal islands. The scanning electron micros-
copy studies did not show any other differences between
Fig 1. Scanning electron assessment of grafts.A,Uncoa
magnification, 1000). B, Adhesive-coated ePTFE (A
ePTFE (R-eP; original magnification, 1000). D, R-ePrapamycin-coated grafts and those coated with adhesivealone. Handling characteristics of the graft material were
maintained during suturing and implantation.
All animals survived until they were killed, with palpa-
ble pulses in the operated hindlimb and patent grafts. None
of the animals developed wound or graft infections. Weight
gain was similar. Aneurysmal degeneration was absent, and
all grafts were well incorporated.
We compared animals that underwent bypass with
uncoated ePTFE grafts with those that underwent by-
pass with adhesive-coated ePTFE to see whether the
vehicle for the rapamycin was responsible for any changes
in the degree of neointimal hyperplasia. There were no
differences in the length of the iliac anastomosis, the
percentage of cross-sectional narrowing, or the intimal
thickness index between the two groups at explantation
(Table II). The coating seemed inert and was not asso-
ciated with a propensity for inflammation or thrombosis.
The data for the two groups were then combined to form
one control group (U-eP and A-eP) for comparison with
xpanded polytetrafluoroethylene (ePTFE;U-eP; original
riginal magnification, 1000). C, Rapamycin-eluting
inal magnification, 2500).ted e
-eP; othe R-eP animals.
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grafts had longer explanted iliac anastomoses (R-eP, 10.3 
0.26 mm; U-eP and A-eP, 7.3 0.15 mm; P .0001). In
addition to having longer anastomoses (85.6% vs 60.6% of
initial anastomotic length maintained; P  .0001), the
R-eP animals had less cross-sectional narrowing in the
outflow graft (16.2% vs 28.5%; P  .0007) and decreased
intimal thickness indexed to ePTFE (Table I).
Complete endothelial coverage of ePTFE was noted in
all groups. R-eP animals had less spindle cell ingrowth and
neointimal formation. They received lower scores than
U-eP and A-eP animals (Table III). Medial necrosis and
aneurysmal degeneration were absent, and there were no
differences in cellular infiltration between the experimental
groups.
Preliminary experiments with waterbaths showed that
the adhesive coating was subject to aqueous attack with
dissolution over a 30-day period. Scanning electronmicros-
copy samples of explanted anastomoses showed coverage of
the internal surface of the ePTFE with cells and biologic
debris. The adhesive coating could not be visualized, and
comparisons of adhesive integrity and thickness between
A-eP and R-eP samples could not be made. It was assumed
that the neointima formed on ePTFE as dissolution of the
adhesive polymeric matrix was occurring.
The ethylene oxide sterilization process did not cause
loss of rapamycin before implantation. Similar drug levels
were detected despite sterilization. Similarly, the rapamycin
fraction was detected 18 minutes after instillation of the
Table II. Comparison of gross pathologic and
morphometric parameters (postoperative day 28) of
neointimal hyperplasia between animals treated with
uncoated (U-eP) and adhesive-coated expanded
polytetrafluoroethylene (A-eP)
Variable
U-eP
(n  6)
A-eP
(n  6) P value
% Initial anastomotic
length 57.3%  3.2% 63.8%  3.2% .17
% Cross-sectional
narrowing 27.4%  4.0% 29.7%  4.0% .68
Intimal thickness
index 1.71  0.20 1.79  0.18 .78
Table III. Pathologic grading of anastomotic cross
sections for neointimal hyperplasia
Variable
U-eP and
A-eP (n  12)
R-eP
(n  10) P value
Neointimal formation 2.5  0.2 0.8  0.2 .0001
Spindle cell ingrowth 2.3  0.3 0.8  0.2 .0007
Endothelialization 3.0  0.0 3.0  0.0 1
U-eP, Uncoated expanded polytetrafluoroethylene; A-eP, adhesive-coated
expanded polytetrafluoroethylene; R-eP, rapamycin-eluting expanded poly-
tetrafluoroethylene; p  NS, numerical score.sample onto the HPLC column, irrespective of steriliza-tion. Table IV shows rapamycin levels obtained from grafts,
explanted arteries, and blood sampled at various time
points. Preliminary HPLC experiments showed that the
coating process resulted in loading of 1 mg of rapamycin
per ePTFE graft before implantation. Results from 9 ani-
mals that were killed temporally to help determine elution
kinetics showed that most rapamycin eluted off the grafts
by 1 week. Levels decreased from 1000 g before implan-
tation to 26.7 g at 1 week after explantation. Drug (2.9
g/g) was detected in the adjacent arterial wall on postop-
erative day 7 and persisted until death. Despite being
present in the arterial wall on postoperative day 28, rapa-
mycin did not reach levels associated with systemic toxicity.
Rapamycin was not detectable in blood after postoperative
day 3.
DISCUSSION
Intimal hyperplasia is initiated by endothelial damage.
Neointimal hyperplasia represents the response of VSMCs
to physical, chemical, and humoral factors in regions of
dysfunctional endothelial regulation. VSMCs are induced
to migrate from the media to the intima, where they
proliferate and deposit ECM.12 Research on the develop-
ment of neointimal hyperplasia has focused on the preven-
tion of arterial restenosis after PTA and implantation of
vascular grafts. The endothelium is disrupted at vascular
anastomoses and at sites of PTA. Use of stents can prevent
recoil and remodeling in treated arteries but does not
eliminate neointimal hyperplasia. Struts from implanted
stents incite an inflammatory response in the adjacent ar-
tery. This response perpetuates restenosis by initiating cy-
tokine release from infiltrating cells. Vascular grafting with
ePTFE also elicits neointimal hyperplasia through alter-
ations in wall shear, flow, and compliance mismatch be-
tween the native artery and the prosthetic.12-14
Pharmacologic manipulation of VSMC migration and
proliferation and ECM production is one approach in the
treatment of restenosis after vascular intervention. Rapamy-
cin is a macrocyclic, lipophilic lactone with immunosup-
pressive antibiotic activity derived from the actinomycete
Streptomyces hygroscopicus. Rapamycin is approved by the
US Food and Drug Administration for the prophylaxis of
renal transplant rejection. Rapamycin has many properties
that make it a good agent to counteract neointimal hyper-
plasia. Rapamycin binds to its cytosolic receptor FK506
binding protein (FKBP-12) and inhibits the mammalian
target of rapamycin. The mammalian target of rapamycin is
a ubiquitous signal transduction kinase that is responsible
for cell-cycle progression. Mammalian target of rapamycin
inactivation results in a reduction of cyclin-dependent ki-
nases and increased levels of p27kip1, a cyclin-dependent
kinase inhibitor. The net effect is to cause G1-S arrest in
proliferating cells such as T cells and VSMCs.15,16 In
addition to inhibiting cellular proliferation, rapamycin inhibits
the migration of VSMCs into areas of vascular injury.17 In
pigs, rapamycin needs to be present in the vessel wall for 14
days after injury to be effective.5,18 The rate of neointimal
proliferation in stented porcine coronary arteries is greatest
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become populated by VSMCs in a proteoglycan-rich ma-
trix. To be effective, rapamycin needs to be present during
the time when the stimulus for VSMC migration and
proliferation exists. Hydrophobic drugs such as rapamycin
may achieve higher mean tissue concentrations in the in-
tima because they are less likely to diffuse back into the
circulation, thus facilitating longer exposure in the area of
injury.19,20
Drug elution has been used with excellent results in
coronary interventions. Paclitaxel- and rapamycin-eluting
stents significantly reduce the incidence of restenosis and
late loss of arterial luminal diameter. Major adverse cardiac
events such as myocardial infarction, death, and target
lesion/vessel revascularization are also decreased with drug-
eluting stents.21,22 Patients treated with bare metal stents
require more frequent coronary interventions. There is no
difference in mortality or incidence of acute myocardial
infarction, but studies to date have not included data to
detect changes in these end points.22 Review of the litera-
ture indicates that drug-eluting stents reduce event rates by
40% to 60% at 12 months.22
Drug-eluting stents have not performed as well in the
infrainguinal circulation. Stenoses and occlusions are more
common in the femoropopliteal region than in the coro-
nary arteries. In addition, lesions here tend to be multiple,
long, heavily calcified, and endophytic. Approximately 90%
of the time, peripheral arteries can undergo successful
angioplasty, but recurrence is common: restenosis occurs in
up to 80% of cases after 1 year. Stenting femoropopliteal
vessels after balloon angioplasty has not substantially im-
proved patency. Nitinol stents may improve these results
because they are less prone to external compression and
elicit less neointimal hyperplasia than more rigid balloon-
expandable stents.23-26 Sirolimus-eluting (rapamycin-elut-
ing), nitinol-expandable SMART (Cordis/Johnson &
Johnson, Warren, New Jersey) stents in the peripheral
circulation have been evaluated in two trials. These trials
have the acronym SIROCCO, which stands for sirolimus-
coated Cordis SMART nitinol self-expandable stent for the
treatment of obstructive superficial femoral artery disease.
SIROCCO I had promising early results, with 0% restenosis
in the drug-eluting arm at 6 months; however, stent frac-
tures were reported in 6 of 33 patients (3 in each treatment
group).27 The 18-month results were mixed, with the
slow-eluting rapamycin stent having 0% restenosis but the
fast-eluting stent having 33% restenosis. By 24 months,
both slow- and fast-eluting coated stents failed to show a
Table IV. Quantification of rapamycin drug levels in graft
Variable Day 0 Day 1 Day
Graft (g) (n  3) 1000 N/A N/
Artery (g/g) (n  3) 0 N/A N/
Blood (ng/mL) (n  3) 16.9  1.8 9.3  0.2 2.0 
N/A, Not applicable.difference from uncoated stents and had a binary restenosisrate of 40%.28 The SIROCCO II trial 18-month data also
failed to show superiority, with a total in-stent binary
restenosis rate of 20.7% for the rapamycin-eluting stent and
17.9% for the uncoated stent arm. Stents in the peripheral
arteries of the lower extremities treat longer, more calcified
lesions in arteries with relatively low flow rates. Stents in the
periphery experience increased biomechanical forces in-
cluding elongation, rotation, and radial compression as a
result of the anatomy of the femoropopliteal vasculature.
The attendant stent deformation may result in stent frac-
tures and neointimal proliferation.9 The greater propensity
for neointimal hyperplasia may require higher levels of drug
than can be eluted locally from coated stents. Also, the use
of self-expanding stents presents new challenges for drug
loading and delivery that do not pertain to coronary stent
technology and that may limit the dose of available drug.
Some might question the impetus to pursue improvement
in peripheral circulation stenting in view of the relative
success that has been achieved by open surgery. The 70% to
80% 5-year patency achieved with bypass surgery (vein and
prosthetic) may be hard to surpass.29
Although metal alloy technology is optimized to de-
crease the propensity for stent deformation and fracture,
improving the performance of prosthetic grafts is still war-
ranted. Prosthetic grafts are not prone to structural damage
and maintain excellent handling characteristics, but small-
diameter (6-mm) grafts are prone to thrombosis. Low
shear and flow separation at prosthetic anastomoses cause
the release of growth factors that result in VSMC prolifer-
ation.12,14 Coating methods that exploit the hydrophobic
nature of the graft and the electronegativity of the graft
surface while avoiding denaturation of the pharmacologic
agent used to modify neointimal hyperplasia are necessary
so that the thromboresistance and biocompatibility of the
ePTFE can be maintained.
In these experiments, the reduction in neointimal hy-
perplasia seen with the rapamycin-eluting ePTFE grafts was
encouraging because the maintenance of anastomotic
length and the decreased percentage of cross-sectional nar-
rowing may translate to improved patency, especially in
small-diameter ePTFE grafts, which are most prone to
failure. Equally important is the fact that the coating pro-
cess does not seem to influence thrombogenicity or alter
arterial healing, as evidenced by complete endothelializa-
tion in all experimental groups. The results need to be
evaluated at longer intervals, because despite apparent
safety, the efficacy seen at 28 days may not persist. Carter et
al30 found that rapamycin-eluting stents inhibited intimal
ery, and blood
Day 3 Day 7 Day 14 Day 28
N/A 26.7  1.4 12.8  5.0 0.005  0.001
N/A 2.9  0.8 1.3  0.2 0.025  0.007
1.9  0.2 0 0 0, art
2
A
A
0.1hyperplasia for 30 days; however, long-term inhibition was
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occurred despite increased levels of p27kip1. In their work,
rapamycin remained present in the arterial wall (0.32 ng/
mg) at 90 days; however, although increased levels of
p27kip1 were detected, there was also increased expression
of proliferating cell nuclear antigen, and this raised the
possibility that factors stimulating neointimal formation
were not inhibited by rapamycin’s effects on the cell
cycle.31-33 In the present experiment, rapamycin was de-
posited in the adjacent arterial wall on postoperative day 7
(2.9 ng/mg or 2.9 g/g). At death, arterial levels of
rapamycin decreased to 0.025 ng/mg. The continued sup-
pression of neointimal hyperplasia despite a 10-fold de-
crease in drug concentration when compared with the
study of Carter et al raises questions about the minimum
doses and durations of exposure that are required for
initiation and maintenance of rapamycin’s therapeutic ef-
fect. It is not known what minimal tissue level of rapamycin
needs to be present to achieve a measurable decrease in
neointimal hyperplasia. The current therapeutic rapamycin
level (8-17 ng/mL) is derived from the blood of patients
receiving prophylaxis against kidney transplant rejection.
Low tissue levels, as evidenced by a lack of rapamycin in the
blood after postoperative day 3, make systemic toxicity
unlikely.
Another cautionary note pertains to the extrapolation
of data from a porcine model to humans. The response of
peripheral porcine arteries to injury is not as well character-
ized and seems less vigorous than that in coronary arter-
ies.34 Humans and pigs exhibit differences in their re-
sponses to rapamycin. Preclinical studies showed a 50%
reduction in neointimal formation at 30 days, and early
human trials showed 80% to 90% inhibition at 6 months.6
This discrepancy may be explained by differences in species
arterial wall substrates. Human trials consisted of athero-
sclerotic vessels, which have more abundant FKBP-12 re-
ceptors, whereas porcine arteries were normal and had
lower levels of FKBP-12.30,35 Pigs may represent a tougher
model for demonstrating decreases in neointimal hyper-
plasia with rapamycin because of their relative paucity of
rapamycin receptors. Paclitaxel-eluting stents used in por-
cine models have also shown modest changes in neointimal
hyperplasia. Preclinical porcine data for the TAXUS SR
(Boston Scientific Corporation, Natick, Massachusetts)
stent failed to show a reduction in neointimal hyperplasia at
28 to 180 days, whereas human clinical data showed reduc-
tions in restenosis at 9 months and a maintenance of effect
up to 3 years after drug-eluting stent implantation.36 Re-
gardless of the limitations, porcine coronary arteries re-
spond to injury by producing a neointima within 28 days
that is similar to that in humans. The amount of neointima
produced is proportional to the degree of injury.37 Despite
limitations in establishing efficacy, the porcine model is
good for establishing safety of an intervention.37
In conclusion, the results of this study confirm the
feasibility and safety of coating ePTFE with rapamycin. At
28 days, rapamycin-eluting ePTFE grafts demonstrate di-
minished gross, pathologic, and morphometric features ofneointimal hyperplasia. These results are with early evalua-
tion of neointimal hyperplasia after implantation and need
to be assessed with longer follow-up to confirm mainte-
nance of efficacy. The data from this study support the
deposition of locally eluted rapamycin into the arterial wall
and its persistence in the artery even after drug has been
eluted from the prosthetic (Table IV). Pharmacologic in-
hibition of VSMC function by rapamycin needs to be
maintained at least until endothelial coverage is achieved at
anastomoses. Arterial injury causes endothelial dysfunc-
tion, VSMC proliferation and migration, phenotype alter-
ation, and ECM deposition during the first 2 to 4 weeks in
a porcine model. In humans, the period of arterial healing is
longer, and rapamycin needs to be present and active in
perianastomotic tissue at least until endothelialization is
complete. Alterations in the kinetics of rapamycin elution
may be required to allow longer exposure of rapamycin to
vessels adjacent to treated anastomoses. Unlike metal stents,
which experience fractures and subsequent neointimal for-
mation when exposed to the biomechanical forces in the
femoropopliteal circulation, rapamycin-eluting ePTFE grafts
may prove superior because handling characteristics and
biocompatibility are preserved. It remains to be seen whether
decreased neointimal proliferation with rapamycin-eluting
ePTFE grafts will translate into improved patency that will
allow more frequent use of prosthetic grafts in situations in
which autologous material is not available and neointimal
hyperplasia is prevalent.
The authors thank Dr Kimberly L. Napoli for expertise
in quantification of rapamycin on ePTFE grafts and in
arterial tissue.
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Dr Randolph Geary (Winston-Salem, NC). Thank you. This
was an interesting manuscript, and I enjoyed having the opportu-
nity to look through it last night after the cigar reception. You are
to be commended on a very nice presentation. I really did enjoy
that.
Drug-eluting stents have clearly been one of the greatest
advances in interventional cardiology to date, with extraordinarily
low rates of restenosis even at late times in real-world patients with
multiple risk factors for restenosis and complex lesions. Thus, it is
only logical that this technology be applied to other vascular beds,
such as the renal and superficial femoral artery and other vascular
devices beyond stents. Thus, the group fromMemphis has taken a
logical next step by coating the ends of PTFE grafts with a polymer
that elutes sirolimus, and they have shown reduced anastomotic
intimal hyperplasia in a graft iliac anastomosis. The data appear
sound, and they justify their conclusions in the context of a
nonatherosclerotic animal model with normal arteries. To help put
these data into clinical context, however, I have a few questions.
Do the authors feel that the aortoiliac model will accurately
predict the biology below the inguinal ligament, where we have the
greatest problem with maintaining graft patency? Clearly, thein mind, a second question, then. In looking at the coated stent
trials in the superior femoral artery, we see at late times that the
restenosis rates are no better in sirolimus-eluting and in bare metal
stents in the SIROCCO trial. This may be related in part to the
duration of the drug elution or to amultitude of other factors, such
as stent fractures. The coating that you used and the amount of
drug that you used—was it similar to what we see with the
drug-eluting stents? Or have you used a much higher dose, some-
thing that is not directly comparable to those clinical data from the
superficial . . . (end of cassette) . . . graft anastomosis but the
incorporation of the PTFE, which is so important in graft healing,
as well on the outside of the graft. Did you notice any differences in
the amount of inflammation either within the lesion or around the
graft?
Again, I enjoyed your presentation and thank you very much
for the opportunity to discuss the paper.
Dr Cagiannos. Thank you for your comments. I am actually
going to start in reverse order.
With respect to inflammation, grafts were well incorporated,
and, in fact, on visual examination at explantation, you couldn’t
really tell differences between rapamycin-eluting grafts and our
uncoated grafts. We also did have our pathologists examine sec-
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data are not presented, but there were no differences with respect
to either the type of cell that infiltrated the graft and the tissue
around the graft or the number of cells that infiltrated. These
findings went against the anti-inflammatory nature of rapamycin.
We coated our grafts with 1 mg of rapamycin (sirolimus). The
SIROCCO trial utilized SMART stents coated with 2.5 mg of
rapamycin. The coronary stents are loaded with about 140 g/
cm2 of rapamycin, giving a range of about 185 to 200 g of
sirolimus. Our grafts are in the mid range. We don’t have as much
sirolimus as the SIROCCO trial, and we don’t have as little as the
coronary stents. Some of the differences with respect to our graft
are that we have a fairly rapid elution of rapamycin but still have
maintenance of drug in the artery. I think some of the coronary
literature shows that the concentration of rapamycin in the artery is
more and that there is more sirolimus remaining on the stents.
With respect to the SIROCCO trial, I don’t think they have
done kinetics to see how much rapamycin is in the tissue or the
grafts, obviously, because the grafts are still in the patients.
With respect to the validity of this model in the infrainguinal
circulation, the greatest impetus for neointimal hyperplasia occurs
in ePTFE grafts, where you are less than 6 mm. We used 6-mm
grafts. To really test this model, one needs to use smaller grafts,
about 4 mm, which can be done in pigs and can have a longer
follow-up. I think the end-to-side anastomotic model is a valid
model because it is normally performed in infrainguinal bypasses
and elicits some of the shear stresses and compliance mismatches
that are seen. This is a nonatherosclerotic model, but it does elicit
neointimal hyperplasia in a relatively short period of time. Review
of the literature shows that pigsmay bemore resistant to rapamycin
because of a relative decrease in the cytosolic receptor, the FK506
binding protein receptor. If one sees changes in this, it may mean
that there is the potential for, and in fact a greater chance of, seeing
results with humans.
I hope that these comments answer your questions and again
thank you for your comments.
Dr Scott Berceli (Gainesville, Fla). Two questions. First, you
focused on the distal anastomosis. Did you look in the midgraft
region, and were there differences? If there weren’t, what are your
thoughts on that? Is it related to an interplay with the hemody-
namics that occur that may sort of affect the healing, or is it in some
way related to the endothelialization that may occur at the distal
anastomosis but not more in the center of the graft?As for my second question, I think the _____’s lab over the last
couple of years has shown that with the amount of intimal hyper-
plasia that develops in prosthetic grafts, as opposed to vein grafts,
the healing occurs with a combination of both proliferation and
significant apoptosis, which you do not see in vein grafts. Have you
sort of looked to see whether the mechanism for decreased intimal
hyperplasia is related to a difference in cell number, and if so, is it
related to differences in proliferation or apoptosis?
Dr Cagiannos. We did do other studies that looked at our
proximal anastomosis and also had sections through the mid graft.
We showed decreased neointimal hyperplasia both at the proximal
and distal anastomoses, in the midgraft morphometrically, and on
gross visual inspection. Our grafts were 6 cm long.
With respect to differences in apoptosis, we did not perform
terminal deoxynucleotidyl transferase–mediated deoxyuridine
triphosphate nick-end labeling staining to examine for apoptosis.
However, we did do some bromodeoxyuridine immunostaining
and showed that there are decreased regions of bromodeoxyuri-
dine uptake in the hyperplastic tissue. Interestingly, the number of
cells that are actually proliferating per square millimeter is the
same, but there were decreased areas of proliferation. At this point,
it appears that we do not block cellular proliferation with rapamy-
cin, but that we decrease regions in the neointimal tissue where it
occurs. I hope those answer some of your questions.
Dr Mitchell Goldman (Knoxville, Tenn). You looked at the
intimal hyperplasia of the graft, but did you look at the intimal
hyperplasia of the vessel?
Dr Cagiannos. We did not do that directly. The equivalent
measurement of that was looking at the maintenance of anasto-
motic length. When we took those anastomoses and sectioned
them open, the anastomotic length is the result of the vessel
growing inward, and I think that was our indirect measurement of
vessel neointimal hyperplasia. We did not look at neointimal for-
mation in the outflow iliac vessel morphometrically, but grossly,
we did not appreciate the white overgrowth of tissue typical of this
lesion in this location.
Dr Goldman. Because, in fact, when we look at graft failures,
the neointimal hyperplasia that vexes us most is really just distal to
the anastomosis and not in the graft.
Dr Cagiannos. That is a good point, and we do have sections
that can still be examined. I think that will be something that can
be done in the future.
